Sanofi’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.9M Hold
2,783,096
– – 4.9% 7
2026
Q2
$36.1M Hold
2,783,096
– – 6.76% 6
2026
Q1
$29.2M Buy
+2,783,096
New +$39.4M 8.69% 5

Other funds holding AGMB

Sanofi's AGMB Position: Q3 2026 in Review

Sanofi held its AgomAb Therapeutics NV (AGMB) position steady in Q3 2026 at 2,783,096 shares worth $30.9M. The position accounts for 4.9% of the portfolio, ranked #7.

Sanofi first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $36.1M in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Sanofi held 2,783,096 shares of AgomAb Therapeutics NV worth $30.9M as of Q3 2026.
  • Sanofi left its AgomAb Therapeutics NV share count unchanged in Q3 2026.
  • AgomAb Therapeutics NV made up 4.9% of Sanofi's portfolio in Q3 2026, its #7 holding.
  • Sanofi first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • Sanofi's AgomAb Therapeutics NV position peaked at $36.1M in Q2 2026.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Sanofi's 13F filing for Q3 2026, filed 5 Nov 2026.